Ethical Considerations Regarding Psychedelics for Clinical Pain Research

Christopher Robinson,Matthew Slitzky,Michael Schatman,R Yong,April Lehman,Ata Murat Kaynar,Sharvari Shivanekar,Trent Emerick

DOI: https://doi.org/10.2147/jpr.s491470

IF: 2.8319

2024-12-18

Journal of Pain Research

Abstract:Christopher L Robinson, 1, &ast Matthew Slitzky, 2, &ast Michael E Schatman, 3, 4 R Jason Yong, 1 April D Lehman, 5 Ata Murat Kaynar, 6 Sharvari P Shivanekar, 7 Trent Emerick 6 1 Department of Anesthesiology, Perioperative & Pain Medicine, Harvard Medical School, Brigham & Women's Hospital, Boston, MA, USA; 2 Burke Rehabilitation, Montefiore Health System, White Plains, NY, USA; 3 Department of Anesthesiology, Perioperative Care, and Pain Medicine, NYU Grossman School of Medicine, New York, NY, USA; 4 Department of Population Health-Division of Medical Ethics, NYU Grossman School of Medicine, New York, NY, USA; 5 Office of Research Protections, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 6 Department of Anesthesiology and Perioperative Medicine, Chronic Pain Division, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 7 Department of Consultation-Liaison Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA &astThese authors contributed equally to this work Correspondence: Trent Emerick, University of Pittsburgh Medical Center, 5750 Centre Ave &num400, Pittsburgh, PA, 15206, USA, Email Psychedelics, substances with a long history of cultural and medicinal use, are experiencing a resurgence in clinical research, particularly in psychiatry. Despite their classification as Schedule I drugs, recent studies suggest therapeutic potential, particularly in treating refractory depression. With chronic pain representing a major health concern and with few non-opioid treatment options available, psychedelics are being explored as alternative treatment modalities. The National Institutes of Health (NIH) now funds psychedelic research, marking a shift from previous decades of limited funding. However, ethical considerations loom large. Vulnerable populations, such as those with chronic pain that impairs their autonomy, require careful consideration by researchers of risks and benefits. Additionally, researchers and interested entities must navigate complex regulatory landscapes involving the United States Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) when considering pursuing possible research. Furthermore, transparent collaboration among stakeholders—patients, researchers, and regulatory bodies—is crucial for participant safety and successful research. Although a number of ethical approaches can be taken, we posit that stakeholders consider utilizing principal-based research ethics, comprised of the principles of autonomy, beneficence, justice, and nonmaleficence, to guide the process. Ultimately, balancing therapeutic promise with ethical integrity is paramount. Careful planning, collaboration, and adherence to ethical principles can increase the likelihood that psychedelic research in chronic pain management progresses responsibly, offering hope for patients while safeguarding their well-being. Keywords: ethics, psychedelics, chronic pain, research, drug enforcement administration Psychedelics represent a broad category of substances that have long existed on the fringe of Western clinical medicine. The term "psychedelic" was coined by psychiatrist Humphrey Osmond and is derived from the ancient Greek words psychē (translated as "soul" or "mind") and dēlein (translated as "to reveal" or "to manifest") - the word literally translates as "mind manifesting" or "soul revealing". 1 Psychedelics were used long before the industrialized world was introduced to them in 1897, when Arthur Heffter isolated mescaline from the peyote cactus. Dating as far back as 5700 years ago, these substances have been used in ancient Greece, Mexico, and India. Psychedelics still remain in use in Native American religious ceremonies and in ritual healing practices in the Amazonian Basin, amongst others. 2–8 Psychedelics enjoyed an enthusiastic interest in psychiatric research up to the late 1960s, after which cultural and political changes along with stricter regulations contributed to the decision to place psychedelics in Schedule I of the 1971 UN Convention on Psychotropic Substances, thus ceasing clinical use and leading to the abrupt decline of research funding. 1,9,10 Over the past decade, there has been a growing body of evidence to suggest that psychedelics may serve a growing therapeutic use in contemporary clinical practice. 10–12 One of the more common areas of clinical study regarding psychedelics is in the field of psychiatry, in which recent studies have demonstrated promising results in regard to psilocybin for use in refractory depression, with funded research exploring other indications such a -Abstract Truncated-

clinical neurology